Companies / BridgeBio Oncology Therapeutics, Inc. / Activity
Activity — BridgeBio Oncology Therapeutics, Inc.
9 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Mehra Uneek Executive | Grant | Common Stock | $0 | +23K | 23,330 0.03% of shares | low |
| Mar 10, 2026 | Beltran Pedro Executive | Grant | Common Stock | $0 | +47K | 46,670 0.06% of shares | low |
| Mar 10, 2026 | Ben Yong Executive | Grant | Common Stock | $0 | +47K | 46,670 0.06% of shares | low |
| Jun 16, 2026 | McCormick Frank Director | Grant | Stock Option (Right to Buy) | — | +32K | 31,675 0.04% of shares | low |
| Mar 24, 2026 | Lebowitz Peter F Director | Grant | Stock Option (Right to Buy) | — | +63K | 63,350 0.08% of shares | low |
| Mar 10, 2026 | Mehra Uneek Executive | Grant | Stock Option (Right to Buy) | — | +105K | 105,000 0.13% of shares | low |
| Mar 10, 2026 | Beltran Pedro Executive | Grant | Stock Option (Right to Buy) | — | +210K | 210,000 0.26% of shares | low |
| Mar 10, 2026 | Ben Yong Executive | Grant | Stock Option (Right to Buy) | — | +210K | 210,000 0.26% of shares | low |
| Jan 1, 2026 | Wallace Eli M. CEO | Grant | Stock Option (Right to Buy) | — | +1.1M | 1,114,400 1.39% of shares | low |